Using the industry peer median EV/Revenue multiple (trailing + forward), Oramed Pharmaceuticals Inc. (ORMP) has a fair value of $1.57 based on 5 comparable companies in the Biotechnology industry.
USD in millions except Fair Price. Subject company highlighted.
| Mkt Cap ($M) | Trailing EV/Revenue | Forward EV/Revenue | |
|---|---|---|---|
| Oramed Pharmaceuticals Inc.ORMP | 173 | 64.2x | 190.5x |
| Ovid Therapeutics Inc. | 369 | 51.0x | — |
| MacroGenics, Inc. | 191 | 1.6x | 2.2x |
| Connect Biopharma Holdings Limited | 133 | 2.1x | — |
| Coya Therapeutics, Inc. | 69 | 2.8x | 10.0x |
| ImageneBio Inc | 59 | 42.7x | 100.5x |
| Industry Median | 2.8x | 10.0x | |
| (*) Revenue | 2 | 1 | |
| = Enterprise Value | 6 | 37 | |
| (-) Net Debt | -45 | -45 | |
| Equity Value | 51 | 82 | |
| (/) Outstanding shares | 42 | 42 | |
| Fair Price | $1 | $2 | |
Using the PEG framework with historical EPS growth of 25.0%, the company has a fair value of $37.50 based on TTM EPS (FY2025) of $1.50. The current PEG ratio is 0.00.
PEG < 1 = bargain, 1–1.5 = fair, > 2 = expensive.
Growth above 25% is capped — hypergrowth may not be sustainable long-term.
| EPS Growth RateHistorical | 971.4% |
| Adjusted Growth (clamped 8–25%)Clamped | 25.0% |
| Fair P/E | 25.0x |
| TTM EPS (FY2025) | $1.50 |
| Fair Value | $37.50 |
No analyst estimates available.
| Year | Net Income | EPS | YoY |
|---|---|---|---|
| FY2021 | $-22.2M | $-0.78 | — |
| FY2022 | $-37.8M | $-0.97 | — |
| FY2023 | $5.5M | $0.14 | — |
| FY2025 | $75.3M | $1.50 | +971.4% |
3Y Historical EPS CAGR: 971.4%
Disclaimer: Sweet Value Lab provides estimated intrinsic values for informational purposes only. This is not financial advice. All models rely on assumptions that may not reflect future performance. Always do your own research before making investment decisions.